| 摘要: |
| 慢性髓细胞白血病(Chronic Myeloid Leukemia,CML)是一种自我更新的造血干细胞恶性增殖肿瘤。第一代酪氨酸激酶抑制剂伊马替尼的问世,为慢性髓细胞白血病患者带来了福音,但随之后来的耐药是一个巨大的挑战,尤其是Bcr-AblT315I突变引发的耐药程度最高。目前已有多种针对T315I突变的靶向治疗药物的研究,包括已上市的Ponatinib等,本文就近年来针对T315I突变的靶向治疗药物做一综述。 |
| 关键词: 慢性髓系白血病 Bcr-AblT315I突变 伊马替尼耐药 靶向治疗 |
| DOI:10.13506/j.cnki.jpr.2017.02.010 |
| 基金项目: |
|
|
|
| Research progress of targeted therapy for chronic myeloid leukemia with Bcr-AblT315I mutation |
| ZHENG Yan1,LI Jiaying1,YANG Yong2,CHEN Zhen1 |
| (1.Pharmaceutical and Medical Basic Experiment Teaching Center,China Pharmaceutical University,Nanjing 211198,China;2.Institute of Pharmaceutical Science,China Pharmaceutical University, Nanjing 211198,China) |
| Abstract: |
| Chronic Myeloid Leukemia (CML) is a self-renewing hematopoietic stem cell malignancy.The advent of the first-generation tyrosine kinase inhibitor—Imatinib has brought the gospel to the CML patients.However,resistance to Imatinib remains a major challenge,especially the Bcr-AblT315I mutations that with the highest resistance.Fortunately,there are many of therapies targeting T315I mutations having been reported,including the currently marketed Ponatinib.This review focused on the research progress of targeted therapies of T315I mutation in recent years. |
| Key words: Chronic Myeloid Leukemia Bcr-AblT315I mutation Imatinib-resistant Targeted Therapy |